07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

Aerinaze desloratadine/pseudoephedrine regulatory update

CHMP issued a positive opinion for the approval of Aerinaze, a combination of 2.5 mg desloratadine and 120 mg pseudoephedrine to treat seasonal allergic rhinitis accompanied by nasal congestion. Schering-Plough Corp. (SGP), Kenilworth, N.J.   Product:...